Health
New head lice treatment approved for use in USA – Mirage News
L – R Hatchtech CEO Hugh Alsop, Associate Professor Vern Bowles and Hatchtech Chairman Paul Kelly. Photo: supplied. A new prescription head lice…
L – R Hatchtech CEO Hugh Alsop, Associate Professor Vern Bowles and Hatchtech Chairman Paul Kelly. Photo: supplied.
A new prescription head lice treatment, developed by University of Melbourne Associate Professor Vern Bowles, has been given Food and Drug Administration (FDA) approval, allowing it to be sold in the USA.
The treatment, Xeglyze™, was developed by Hatchtech, an Australian pharmaceutical company and will be commercialised by Dr Reddy’s Laboratories.
Hatchtech CEO Hugh Alsop estim…
-
Business22 hours ago3 ASX 200 shares set to dominate the next decade
-
Business8 hours ago3 of the best ASX shares to buy with $5,000
-
Business24 hours agoForget CBA, Macquarie is tipping a 40% return for this ASX financial stock
-
Noosa News21 hours agoTwo young girls charged following a string of assaults and robberies in Queensland’s south east